Pharma & Biotech Global Week in Review 2 March from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Humira (Adalimumab) – US: $1.67B verdict overturned by CAFC, patent invalidated over written description: Centocor v Abbott (Peter Zura’s 271 Patent Blog) (Patently-O) (Patently-O) (Patent Law Practice Center) (Patent Docs) (IPBiz)

Fexofenadine – Australia: Anti-histamine inventive… but not novel, says Federal Court!: Albany Molecular Research v Alphapharm (Patentology) (IP Whiteboard) (IP Whiteboard)

Australia: Anti-gene-patents bill introduced in Lower House (Patentology) (IP Whiteboard) (Patent Baristas) (PatentlyBIOtech)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

WHO members to work to disentangle problem of fake medicines, IP issues (IP Watch) (IP Watch) (IP Watch)

Long week ahead for WIPO experts considering treaty on IP and genetic resources (IP Watch)

Negotiators work from new text of traditional knowledge treaty at WIPO (IP Watch) (IP Watch)

Australia: Anti-gene-patents bill introduced in Lower House (Patentology) (IP Whiteboard) (Patent Baristas)

Australia: BIO submits comments on Australian Senate Patent Amendment (PatentlyBIOtech)

EU: PDL Biopharma announces European Patent Office determination of validity of PDL’s European patent is final (GenericsWeb)

US: Authorised generics again under fire in Senate bill (Patent Docs)

US: BIO comments on USTR on 2011 Special 301 Review (PatentlyBIOtech)

US: Reach of the Bayh-Dole Act to be considered by the Supreme Court: Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc. (Maier & Maier)

US: Undermining a preliminary injunction via patent reexamination: Celsis In Vitro v CellzDirect (Patents Post Grant Blog)

US: Human Genome Sciences’ lawsuit alleges Genentech, Celltech colluded to fraudulently extend Cabilly patent (GenericsWeb)

US: Regeneron files for declaratory judgment of non-infringement and/or invalidity of Genentech patents based on it biological license application for VEGF Trap (Patent Docs)

US 7,893,315: Derivation of embryonic stem cells and embryo-derived cells (IPBiz)

US: Snowmageddon, a government shutdown, and other acts of nature (mother or human) – What are the effects on FDA approval decision deadlines? (FDA Law Blog)

Products

Abraxane (Paclitaxel) – Global: Elan and Celgene enter into settlement and license agreement related to Abraxane (GenericsWeb)

Angiomax (Bivalirudin) – US: The Medicines Company files patent infringement complaint against Mylan following Para IV certification filing (Patent Docs)

Aprovel (Irbesartan), Geodon (Ziprasidone) – Brazil: Pipeline system: extending solution is not the same as extending patent validity (IP tango)

Fexofenadine – Australia: Anti-histamine inventive… but not novel, says Federal Court!: Albany Molecular Research v Alphapharm (Patentology) (IP Whiteboard) (IP Whiteboard)

Glivec (Imatinib) – India: Novartis asked to end challenge to Indian patent law (GenericsWeb)

Humira (Adalimumab) – US: $1.67B verdict overturned by CAFC, patent invalidated over written description: Centocor v Abbott (Peter Zura’s 271 Patent Blog) (Patently-O) (Patently-O) (Patent Law Practice Center) (Patent Docs) (IPBiz)

Nuvaring (Etonogestrel/Ethinyl estradiol) – US: Femina files new 337 complaint regarding certain vaginal ring birth control devices (ITC 337 Law Blog) (ITC 337 Update)

Temodar (Temozolomide) – US: CAFC declines to take prosecution laches en banc: Cancer Research Technology v Barr Laboratories (Patently-O)

Vivelle-Dot (Estradiol) – US: Noven files Hatch-Waxman case against Mylan related to Vivelle-Dot (IPBiz) (SmartBrief)

Xalatan (Latanoprost) – EU: Update on antitrust case against Pfizer (Kluwer Patent Blog)

Xyzal (Levocetirizine) – US: FDA denies Xyzal carve-out petition; another precedent added to the generic drug labeling carve-out citizen petition scorecard (FDA Law Blog) (FDA Law Blog)

One Comment on “Pharma & Biotech Global Week in Review 2 March from IP Think Tank

  1. Here is Similar Story

    The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,683 other followers

%d bloggers like this: